Fresenius Medical Care stock slips after guidance revision but stays supported by analyst coverage

Fresenius Medical Care stock (ISIN DE0005785802) is trading just below the 40-euro mark in early September 2026, with intraday quotes around 39.31 EUR on German venues as of September 4, 2026 according to a market overview on finanzen.net. For investors, the combination of a revised profit guidance and a cluster of recent analyst ratings now shapes the picture for the dialysis specialist.

Guidance revision and current figures

According to the Fresenius Medical Care overview on finanzen.net, the share is quoted at 39.31 EUR on September 4, 2026, with a recent closing level also at 39.31 EUR and an intraday low near 38.44 EUR. That implies the price currently trades noticeably below the mid-40-euro range seen earlier in 2026 and indicates a pullback from higher levels in recent months.

In the same data overview, a revised profit guidance is highlighted for Fresenius Medical Care in 2026, signaling that management has adjusted its earnings expectations compared with previous indications. While exact targets are not detailed in the quote snapshot, the revision is enough for many investors to reassess valuation and growth assumptions for the global dialysis provider. Historical context matters here: in the last reported fiscal year within the freshness window, Fresenius Medical Care generated multi-billion-euro revenue, and profitability metrics such as operating margin and net income remained central to analyst modelling.

Analyst ratings shape the debate

The finanzen.net overview also shows that several major analyst houses have updated their stance on Fresenius Medical Care stock during August 2026, providing a dense set of opinions for the market to digest. On August 6, 2026, DZ Bank issued a rating categorized as Buy for Fresenius Medical Care, indicating that the house sees upside from the current valuation and expects earnings and cash flows to support that view. On the same day, Barclays Capital set its rating to Equal Weight, signaling a more neutral stance and reflecting a view that the risk-reward profile is broadly in line with the sector.

A day earlier, on August 5, 2026, JPMorgan Chase & Co. moved to an Underweight stance on Fresenius Medical Care, while Goldman Sachs Group Inc. classified the share as Neutral according to the same finanzen.net analyst summary. This mix of Buy, Equal Weight, Underweight and Neutral assessments across houses underlines that the stock sits at an interesting crossroads where small changes in margins or volume growth could tilt sentiment in either direction. For retail investors, that range of ratings is a reminder to look carefully at the most recent quarterly figures and guidance rather than relying on a single recommendation.

Trading on German venues and sector context

Fresenius Medical Care shares continue to trade on multiple German exchanges, including Stuttgart and Tradegate, with recent prices at 38.52 EUR on the Stuttgart exchange and 38.70 EUR on Tradegate as of September 3, 2026, again according to the finanzen.net quote overview. Compared with the 39.26 EUR prior-day reference on those venues, this implies a day-on-day decline of about 1.88% on Stuttgart and 1.43% on Tradegate, a move that corresponds with the broader adjustment after the revised profit guidance mention. For investors who use German platforms as their primary access point to the stock, these levels serve as practical benchmarks.

The same overview classifies Fresenius Medical Care as a low-risk title since April 17, 2026, based on volatility and other risk metrics tracked on the portal. At the same time, the valuation is characterized as strongly undervalued in that snapshot, indicating that the share price sits below many models of intrinsic value even after the guidance adjustment. This combination of a low-risk classification and undervalued status is unusual and helps explain why some houses like DZ Bank maintain Buy ratings despite the presence of more cautious views from others.

Dialysis services and treatment systems

Fresenius Medical Care is globally known for its dialysis services and dialysis treatment systems, which form the core of its business model and revenue generation. The company operates a large network of dialysis clinics and supplies equipment such as dialysis machines and related consumables to healthcare providers worldwide. In recent years, the focus has increasingly been on improving treatment outcomes and patient comfort, which drives demand for advanced dialysis technologies and integrated care concepts.

Among its product portfolio, Fresenius Medical Care offers modern dialysis machines designed for both acute and chronic kidney failure treatment. These systems, combined with software, disposables and service offerings, create recurring revenue streams and underpin the companys ability to scale over time. For investors, growth in treatment volumes, reimbursement trends and innovation in equipment all feed directly into the key figures that analysts watch, such as revenue growth rates per region and margins in the products and services segments.

Stock price and investor perspective

As of September 4, 2026, Fresenius Medical Care stock is quoted around 39.31 EUR on German trading platforms, with recent prices between roughly 38.52 EUR and 38.70 EUR on Stuttgart and Tradegate on September 3, 2026, according to the finanzen.net data. These levels place the share below earlier mid-40-euro prices in 2026, reflecting the impact of the revised profit guidance but still leaving room for potential upside if margins and growth develop favorably.